IP Library Granted Patent US 7,598,028
Granted Patent B2
US 7,598,028 · App. 11/946,676 · Granted Oct 6, 2009

Compositions and methods for detecting and treating prostate disorders

Assignee: The Regents of the University of Michigan
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,598,028
App. No.
11/946,676
Granted
Oct 6, 2009
Kind
B2
Abstract

The present invention relates to compositions and methods for the detecting, treating, and empirically investigating cellular proliferation disorders and cellular motility disorders. In particular, the present invention provides compositions and methods for using CXCL chemokines (e.g., CXCL1, CXCL5, CXCL6, CXCL12), CXCL receptors (e.g., CXCR1, CXCR2, CXCR4, CXCR7), and/or pathway related compounds (e.g., NF-kappaB, ERK ½, ELK-1) in the diagnosis, treatment, and empirical investigation of prostate disorders (e.g., prostate cancer, benign prostatic hypertrophy, prostatitis).

Claims (9)

1. A method for characterizing prostate tissue in a subject, comprising:

a) providing a sample from a subject suspected of having a prostatic disease, wherein said subject has a PSA level at or less than 10 ng/ml, wherein said sample is selected from the group consisting of prostate tissue, serum, plasma, mucus, blood, and urine;

b) detecting and comparing the amount of expression of CXCL5 and CXCL12 in said prostate tissue sample; and

c) characterizing said prostate tissue sample as indicative of prostate cancer or benign prostatic hyperplasia based upon said comparing, wherein a higher amount of detected CXCL12 expression than CXCL5 expression is indicative of prostate cancer, wherein a higher amount of detected CXCL12 expression than CXCL5 expression is indicative of prostate cancer.

2. The method of claim 1 , wherein said detecting the amount of expression of CXCL5 and CXCL12 comprises detecting the amount of CXCL5 and CXCL12 polypeptide.

3. The method of claim 2 , wherein said detecting the amount of expression of a CXCL5 and CXCL12 polypeptide comprises exposing said CXCL5 and CXCL12 polypeptide to an antibody specific to said CXCL5 and CXCL12 polypeptide and detecting the amount of binding of said antibody to said CXCL5 and CXCL12 polypeptide.

4. The method of claim 1 , wherein said subject comprises a human subject.

5. The method of claim 1 , wherein said sample comprises tumor tissue.

6. The method of claim 1 , further comprising the step of c) providing a prognosis to said subject.

Assignments (2)
EXECUTIVE ORDER 9424, CONFIRMATORY LICENSE Recorded Sep 23, 2008
From: UNIVERSITY OF MICHIGAN
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 021571/0100 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 12, 2008
From: MACOSKA, JILL A.
To: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
Reel/Frame 020936/0842 →
Continuity (3)
Provisional Application 6086134600 · Nov 28, 2006
Provisional Application 6094945200 · Jul 12, 2007
Related Publication 20080206766A1 · Aug 28, 2008